en · de · es · fr · pt
cjc-1295-notes.peptides1004.com › Guide › Background And Naming Conventions — Common Mistakes

Background And Naming Conventions — Common Mistakes

By Editorial Desk · published 2026-01-03 · last reviewed 2026-02-22 · Guide

Everything below concerns DAC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-02-22. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Naming Conventions

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Receptor Action and Clearance

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Cjc-1295 at a glance

PropertyValueNotes
Molecular classSynthetic peptideAnalog of growth hormone-releasing hormone
Chain length29 amino acidsBased on the GRF(1-29) fragment
AppearanceWhite to off-white lyophilized powderCommon research supply form
SolubilitySoluble in water and aqueous buffersPowder requires reconstitution before use
Typical storage−20 °C or belowKept away from light and moisture

Compound Identity and Development History

CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

Related pages on this site

Receptor Action and Pharmacokinetics

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

Further detail

=== BASF refounded (1952) === On 28 July 1948, an explosion occurred at a BASF site in Ludwigshafen, killing 207 people and injuring 3818. In 1952, BASF was refounded under its name following the efforts of former Nazi Party member Carl Wurster, who served in Nazi Germany as Wehrwirtschaftsführer (war economy leader). With the German economic miracle in the 1950s, BASF added synthetics such as nylon to its product range. BASF developed Polystyrene in the 1930s and invented Styropor in 1951.

== Etymology == The word ant and the archaic word emmet are derived from ante, emete of Middle English, which come from ǣmette of Old English; these are all related to Low Saxon e(e)mt, empe and varieties (Old Saxon emeta) and to German Ameise (Old High German āmeiza). All of these words come from West Germanic *ǣmaitjōn, and the original meaning of the word was "the biter" (from Proto-Germanic *ai-, "off, away" + *mait- "cut"). The study of ants is called myrmecology, from Ancient Greek μύρμηξ mýrmēx ("ant"). It has been hypothesised that a Proto-Indo-European word *morwi- was the root for Sanskrit vamrah, Greek μύρμηξ mýrmēx, Latin formīca, Old Church Slavonic mraviji, Old Irish moirb, Old Norse maurr, Dutch mier, Swedish myra, Danish myre, Middle Dutch miere, and Crimean Gothic miera.

=== APOA-I: A Possible Novel Biomarker for Metabolic Side Effects in First Episode Schizophrenia === The authors of this study sought to determine the effect on metabolism of the drug risperidone in schizophrenia patients. After discovering that risperidone did have negative metabolic side effects, they tested membrane proteins for glucose and lipid transport in control and experimental groups by MALDI-TOF and fingerprinting. Results showed altered fingerprints and therefore altered levels of folding in the proteins. So, they concluded that risperidone negatively effects glucose and lipid transport proteins in the cell membranes of patients.

Acrodermatitis chronica atrophicans (Herxheimer disease, primary diffuse atrophy) Actinic elastosis (solar elastosis) Anetoderma (anetoderma maculosa, anetoderma maculosa cutis, atrophia maculosa cutis, macular atrophy) Blepharochalasis Cutis laxa (chalazoderma, dermatochalasia, dermatolysis, dermatomegaly, generalized elastolysis, generalized elastorrhexis, pachydermatocele) Cutis rhomboidalis nuchae Ehlers–Danlos syndrome (cutis hyperelastica, elastic skin, India rubber skin) Elastosis perforans serpiginosa Homocystinuria Jadassohn–Pellizzari anetoderma Linear focal elastosis (elastotic striae) Loeys–Dietz syndrome Marfan syndrome Occipital horn syndrome Osteogenesis imperfecta (Lobstein syndrome) Perforating calcific elastosis (localized acquired cutaneous pseudoxanthoma elasticum, perforating periumbilical calcific elastosis, periumbilical perforating pseudoxanthoma elasticum) Pseudoxanthoma elasticum (Grönblad–Strandberg syndrome) Reactive perforating collagenosis Schweninger–Buzzi anetoderma Sclerotic fibroma Striae atrophicans Striae distensae Ullrich disease Verrucous perforating collagenoma Wrinkly skin syndrome

Sources: en.wikipedia.org

Supporting material

== Catalysis == The sortase B enzyme catalyzes a cell wall sorting reaction with a surface protein where a signal NXTN motif is cleaved. In the result, the C-end of the protein is covalently attached to a pentaglycine cross-bridge through an amide linkage, thus tethering the C-terminus of protein A to the cell wall. It cleaves the protein precursor molecule at the NPQTN motif. The peptide bond between T and N of the NPQTN sorting motif is cleaved to form a tetrahedral acyl intermediate. The amino groups of the pentaglycine cross-bridges linked to the lipid II peptidoglycan precursor molecules are thought to function as nucleophile resolving acyl intermediates and creating an amide bond between the surface protein and lipid II with subsequent incorporation of this intermediate into the cell wall envelope. IsdC remains buried within the cell wall, not surface located like IsdA and IsdB anchored by Sortase A. This whole system work together to scavenge iron from haemoglobin.

VUV absorbance spectra also exhibit feature similarity within compound classes, meaning VUV detectors can rapidly compound class characterization in complex samples through compound spectral shape and retention index information. Advances in technology reduces the typical group analysis data processing time from 15 to 30 minutes to <1 minute per sample.

=== Summum === In 1975, an esoteric organization by the name of Summum introduced "Modern Mummification", a service that utilizes modern techniques along with aspects of ancient methods of mummification. The first person to formally undergo Summum's process of modern mummification was the founder of Summum, Summum Bonum Amen Ra, who died in January 2008. Summum is currently considered to be the only "commercial mummification business" in the world.

Sources: en.wikipedia.org

Supporting material

=== Iron chelation === Multiple blood transfusions lead to severe iron overload, as the body eventually breaks down the hemoglobin in donated cells. This releases iron which it is unable to excrete. Iron overload may be treated by chelation therapy with the medications deferoxamine, deferiprone, or deferasirox. Deferoxamine is only effective as a daily injection, complicating its long-term use. Adverse effects include primary skin reactions around the injection site and hearing loss. Deferasirox and deferiprone are both oral medications, whose common side effects include nausea, vomiting and diarrhea.

Viral hemorrhagic fevers (VHFs) are a diverse group of infectious diseases characterized by fever and systemic damage to the circulatory system caused by RNA viruses. Viral hemorrhagic fevers cause symptoms ranging from mild to life-threatening, depending on the virus involved, but generally cause internal bleeding that leads to sudden onset of muscle pain, fever, and hypotension. In severe cases, it can cause life-threatening shock and bleeding from internal organs. While some VHFs are generally mild, such as nephropathia epidemica (caused by two species of hantavirus), many are debilitating or lethal without treatment. Outbreaks of VHFs tend to have high case fatality rates and disproportionately affect communities with poor health infrastructure. Therefore, the emergence of VHFs is a growing public health concern. VHFs are often zoonoses, meaning they can be transmitted from wild animals to human populations; for instance, the Lassa arenavirus is spread by mice. Viral hemorrhagic fevers are caused by members of seven families of single-stranded RNA viruses: Arenaviridae, Filoviridae, Flaviviridae, Nairoviridae, Phenuiviridae, Hantaviridae and Peribunyaviridae.

On 23 May 2026, 12 militants were killed in fighting with the police forces in Bannu District, whereas a retired FCB personnel was also killed and four policemen and a child were injured in the clashes, the death toll rose to 25 militants, two policemen and two civilians, the next day while seven policemen and three civilians were injured, a 10kg IED was also defused. Punjab CTD also claimed to have captured and arrested 13 "suspected terrorists" in 58 raids throughout the province. On 24 May 2026, 11 TTP militants were killed in a series of operations in North Waziristan and two more in Lakki Marwat. Militants destroyed a school and a health center in Tank District.

Sources: en.wikipedia.org

Frequently asked questions

Does this compound occur naturally in the body?

No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.

What does the abbreviation DAC refer to?

DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.

Why do different sources report different half-lives for the same name?

Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.

Which receptor does the compound target?

It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.

Network